467 related articles for article (PubMed ID: 32141173)
1. Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea.
Yoon K; Kim N; Lee JW; Yoon H; Shin CM; Park YS; Lee DH
Helicobacter; 2020 Jun; 25(3):e12685. PubMed ID: 32141173
[TBL] [Abstract][Full Text] [Related]
2. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
[TBL] [Abstract][Full Text] [Related]
3. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
[TBL] [Abstract][Full Text] [Related]
4. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy.
Chung JW; Lee JH; Jung HY; Yun SC; Oh TH; Choi KD; Song HJ; Lee GH; Kim JH
Helicobacter; 2011 Aug; 16(4):289-94. PubMed ID: 21762268
[TBL] [Abstract][Full Text] [Related]
5. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
[TBL] [Abstract][Full Text] [Related]
6. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
7. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
[TBL] [Abstract][Full Text] [Related]
8. Eradication of Helicobacter pylori infection after ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days.
Knigge K; Kelly C; Peterson WL; Fennerty MB
Aliment Pharmacol Ther; 1999 Mar; 13(3):323-6. PubMed ID: 10102965
[TBL] [Abstract][Full Text] [Related]
9. Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice.
Zullo A; De Francesco V; Bellesia A; Vassallo R; D'Angelo A; Scaccianoce G; Sacco R; Bresci G; Eramo A; Tanzilli A; Ridola L; Alvaro D; Londoni C; Brambilla G; Manta R; Di Ciaula A; Portincasa P
J Gastrointestin Liver Dis; 2017 Sep; 26(3):225-229. PubMed ID: 28922433
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy.
Lee SK; Lee SW; Park JY; Kwon BS; Kim SY; Hyun JJ; Kim JH; Jung SW; Koo JS; Yim HJ; Choi JH
Helicobacter; 2011 Oct; 16(5):410-4. PubMed ID: 21923688
[TBL] [Abstract][Full Text] [Related]
11. New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.
Tursi A; Di Mario F; Franceschi M; De Bastiani R; Elisei W; Baldassarre G; Ferronato A; Grillo S; Landi S; Zamparella M; De Polo M; Boscariolo L; Picchio M
Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28125857
[TBL] [Abstract][Full Text] [Related]
12. Esomeprazole, minocycline, metronidazole and bismuth as first-line and second-line regimens for Helicobacter pylori eradication.
Song ZQ; Zhou LY
J Dig Dis; 2016 Apr; 17(4):260-7. PubMed ID: 26946480
[TBL] [Abstract][Full Text] [Related]
13. [The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure in Helicobacter pylori Eradication].
Kwon S; Lee DH; Kang JB; Kim N; Park YS; Shin CM; Yoon H; Choi YJ
Korean J Gastroenterol; 2018 Apr; 71(4):196-203. PubMed ID: 29684968
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.
Kahramanoğlu Aksoy E; Pirinçci Sapmaz F; Göktaş Z; Uzman M; Nazlıgül Y
Med Princ Pract; 2017; 26(6):523-529. PubMed ID: 29131124
[TBL] [Abstract][Full Text] [Related]
15. Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for
Kim SJ; Chung JW; Woo HS; Kim SY; Kim JH; Kim YJ; Kim KO; Kwon KA; Park DK
World J Gastroenterol; 2019 Dec; 25(46):6790-6798. PubMed ID: 31857780
[TBL] [Abstract][Full Text] [Related]
16. Second-line bismuth-containing quadruple therapy for
Kim SE; Park MI; Park SJ; Moon W; Kim JH; Jung K; Kim HK; Lee YD
World J Gastroenterol; 2017 Feb; 23(6):1059-1066. PubMed ID: 28246480
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.
Liang X; Xu X; Zheng Q; Zhang W; Sun Q; Liu W; Xiao S; Lu H
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):802-7.e1. PubMed ID: 23376004
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies.
Georgopoulos SD; Ladas SD; Karatapanis S; Triantafyllou K; Spiliadi C; Mentis A; Artikis V; Raptis SA
Aliment Pharmacol Ther; 2002 Mar; 16(3):569-75. PubMed ID: 11876712
[TBL] [Abstract][Full Text] [Related]
19. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE
Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636
[TBL] [Abstract][Full Text] [Related]
20. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori.
Delchier JC; Malfertheiner P; Thieroff-Ekerdt R
Aliment Pharmacol Ther; 2014 Jul; 40(2):171-7. PubMed ID: 24863854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
